Pinder named Cancer Moonshot Scholar by NCI
College of Medicine faculty member among first receiving honor
Leeya Pinder, MD, MPH, associate professor in the UC College of Medicine Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, is among the first 11 people named as Cancer Moonshot Scholars by the National Cancer Institute (NCI).
The Cancer Moonshot Scholars program is designed to advance cancer science while also diversifying the pool of researchers and the approaches to cancer research that NCI funds. The program is supported by the White House’s Cancer Moonshot initiative and aligns with NCI’s Equity and Inclusion Program and NIH’s UNITE Initiative. The Cancer Moonshot Scholars program is led by the Center to Reduce Cancer Health Disparities. NCI intends to fund up to 30 additional Cancer Moonshot Scholars.
Leeya Pinder, MD, MPH, associate professor in the UC College of Medicine Department of Obstetrics and Gynecology. Photo/Dan Davenport/UC College of Medicine
Pinder’s project is “Repurposed Antiretroviral Therapies to Eliminate Cervical Cancer (POLESA Trial).” Her R37 is a seven-year award totaling $2.75 million during the first five years, with additional funding coming during the project’s last two years.
The overall goal of Pinder’s project is to find new, non-invasive, easily scalable solutions that address the profound gap in secondary cervical cancer prevention, particularly among women living with HIV. The study, which will enroll 180 women who present for cervical cancer screening in a Cervical Cancer Prevention Program clinic in Zambia, will also assess the safety and acceptability of a vaginal capsule containing the protease inhibitors lopinavir and ritonavir given alone or in combination with thermal ablation to treat screened women found with precancerous abnormalities that are eligible for ablative therapy.
Related Stories
UC cancer research presented at national meeting
May 26, 2023
University of Cincinnati Cancer Center researchers will present abstracts at the American Society of Clinical Oncology (ASCO) annual meeting 2023, held in Chicago June 2-6.
OncLive and Targeted Oncology: Drug yields long-lasting benefits to treat PEComa tumors
March 22, 2024
OncLive and Targeted Oncology covered research presented by the University of Cincinnati's Thomas Herzog that found patients with perivascular epithelioid sarcoma (PEComa) of gynecologic or peritoneal origin experienced rapid, durable responses when treated with the drug nab-sirolimus.
Pinder named Cancer Moonshot Scholar by NCI
August 9, 2023
Dr. Leeya Pinder, is among the first named as Cancer Moonshot Scholars by the National Cancer Institute.